MARKET

CUE

CUE

Cue Biopharma Inc
NASDAQ
0.5530
-0.0081
-1.44%
After Hours: 0.5959 +0.0429 +7.76% 19:55 12/04 EST
OPEN
0.5611
PREV CLOSE
0.5611
HIGH
0.5898
LOW
0.5530
VOLUME
193.12K
TURNOVER
--
52 WEEK HIGH
1.750
52 WEEK LOW
0.5400
MARKET CAP
43.54M
P/E (TTM)
-1.2143
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CUE last week (1124-1128)?
Weekly Report · 3d ago
Cue Biopharma Releases Updated Corporate Presentation
TipRanks · 11/24 17:00
Weekly Report: what happened at CUE last week (1117-1121)?
Weekly Report · 11/24 10:04
Cue Biopharma Announces CMO Departure
TipRanks · 11/20 21:37
Cue Biopharma Chief Medical Officer Matteo Levisetti to Depart
Reuters · 11/20 21:00
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 11/19 12:05
Weekly Report: what happened at CUE last week (1110-1114)?
Weekly Report · 11/17 10:03
Cue Biopharma, ImmunoScape enter exclusive in-licensing deal
TipRanks · 11/13 18:20
More
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

Webull offers Cue Biopharma Inc stock information, including NASDAQ: CUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CUE stock methods without spending real money on the virtual paper trading platform.